Ask AI
ProCE Banner Activity

VERITAC-2: Phase III Study of Vepdegestrant vs Fulvestrant in Previously Treated ER-Positive/HER2-Negative Advanced Breast Cancer

Conference Coverage
Slideset

In the phase III VERITAC-2 study, vepdegestrant was associated with a significant improvement in PFS vs fulvestrant in patients with previously treated ESR1-mutated ER+/HER2- advanced breast cancer.

Released: June 03, 2025

Expiration: December 02, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.